<DOC>
	<DOCNO>NCT00026078</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness docetaxel ifosfamide treat woman metastatic breast cancer .</brief_summary>
	<brief_title>Docetaxel Ifosfamide Treating Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy docetaxel ifosfamide first-line chemotherapy woman metastatic breast cancer . - Determine response rate duration response patient treat regimen . - Determine time treatment failure survival patient treat regimen . - Determine toxicity regimen patient . - Determine quality life patient treat regimen . OUTLINE : This multicenter study . Patients receive docetaxel IV 1 hour day 1 ifosfamide IV 1 hour ( begin 1 hour docetaxel infusion ) day 1-3 . Treatment continue every 4 week absence disease progression unacceptable toxicity . Quality life assess baseline , every month study , every 3 month completion study . Patients follow every 3 month . PROJECTED ACCRUAL : A total 15-42 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic breast cancer Bidimensionally measurable lesion The following consider measurable : Bone lesion Leptomeningeal disease Ascites Pleural/pericardial effusion Inflammatory breast disease Lymphangitis cutis/pulmonis Disease progression hormonal therapy allow provide least 1 month since last therapeutic manipulation No CNS metastases Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 21 75 Sex : Female Menopausal status : Not specify Performance status : ECOG 02 OR Zubrod 02 Life expectancy : More 12 week Hematopoietic : WBC least 4,000/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 11 g/dL Hepatic : Bilirubin great 1.25 time upper limit normal ( ULN ) SGOT great 1.25 time ULN Renal : Creatinine clearance least 60 mL/min Cardiovascular : No history congestive heart failure No myocardial infarction within past 6 month No active ischemic heart disease No uncontrolled hypertension Other : Not pregnant No prior concurrent malignancy except properly treat basal cell skin cancer carcinoma situ cervix No medical psychiatric disease would preclude study No geographical situation would preclude study No history alcohol abuse PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior adjuvant chemotherapy include ifosfamide docetaxel No prior systemic chemotherapy metastatic breast cancer Endocrine therapy : See Disease Characteristics No concurrent corticoid , gestagens , androgens unless strictly indicate Radiotherapy : Not specify Surgery : Not specify Other : No concurrent drink contain caffeine alcohol</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>